NOMURA FINANCIAL PRODUCTS EUROPE GMBH
Location
MILANO
Founded
2018-12-12
Website
Risk Signals
1356 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Miscellaneous business Credit Institutions), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about NOMURA FINANCIAL PRODUCTS EUROPE GMBH
Live alerts from global media, monitored by Business Radar
2025-05-31 (moneycontrol.com)
CEAT stock jumps 2% as Nomura, CLSA cite growth in exports, market share
CEAT share price: The company's March 2025 quarter performance was mixed, with strong revenue growth offset by a decline in profit.
Read more
2025-05-30 (longportapp.com)
Nomura: Gives CSPC PHARMA a target price of HKD 8.02 with a rating of "Buy"
Nomura released a research report stating that it has set a target price of HKD 8.02 for CSPC PHARMA, with a rating of "Buy." The report indicates that CSPC PHARMA's performance in the first quarter of 2025 was weak, with revenue decreasing by 21.9% year-on-year to RMB 7 billion (the same below), lower than the expected RMB 8.8 billion, and profit decreasing by 8.4% year-on-year to RMB 1.5 billion, also below the expected RMB 2.4 billion. The gross profit margin decreased by 5.2 percentage points year-on-year to 67.1%, with the gross profit margin for pharmaceutical sales being lower than the firm's expectations, mainly due to adverse changes in the product mix
Read more
2025-05-30 (businessupturn.com)
Nomura maintains 'Buy' on Alkem Labs; expects Semaglutide launch to drive future growth |
Nomura has reiterated its Buy rating on Alkem Labs with a target price of ₹5,430, viewing the Q4FY25 earnings as largely in line on sales, though EBITDA and PAT came in 2% and 6% below estimates, respectively. The company's FY26 guidance is described as a mixed bag. One key concern is an expected rise in […]
Read more
2025-05-29 (ndtvprofit.com)
Sansera Engineering Q4 Review: Price Target Cut By Nomura As Exports Weaken
Sansera Engineering had its target price reduced from Rs 1,669 to Rs 1,643 per share by Nomura amid possible tailwinds from US trade tariffs. The research firm maintained its 'buy' stance on the company as fourth quarter margins were in line with its estimates. Ebitda margin was at 16.3%, in line with Nomura's estimate but lower than consensus estimate of 17.2%. Profit After Tax increased 28% on lower interest expense and higher other income.
Read more
2025-05-26 (businessupturn.com)
Balkrishna Industries shares fall 9% after Nomura downgrade, warns of margin risks in new tyre segments |
Shares of Balkrishna Industries Ltd plunged 9.37% to Rs 2,411.00 on Monday, following a downgrade by global brokerage firm Nomura, which revised its rating to 'neutral' from 'buy' and cut the price target to Rs 2,644 from Rs 3,242. The revised target is nearly in line with Friday's closing price of Rs 2,660.20. The stock […]
Read more
2025-05-26 (businessupturn.com)
Nomura retains 'Neutral' call on Glenmark; Q4 results miss and weak domestic performance weigh on outlook |
Nomura has kept its 'Neutral' stance on Glenmark Pharmaceuticals with a target price of ₹1,500 after the company reported Q4FY25 results below expectations, alongside a significant miss on its full-year guidance. Glenmark posted an exceptional loss of ₹370 crore, which significantly impacted its bottom line. Revenue growth across key geographies—barring Europe, which posted a 20% […]
Read more
2025-05-24 (longportapp.com)
Nomura lowers Weibo's target price to $10, indicating that the advertising business seems to have bottomed out
Nomura has lowered its target price for Weibo to $10, believing that its advertising business seems to have bottomed out. Weibo's first-quarter profit exceeded expectations, with total revenue of $397 million flat, and non-GAAP operating profit rising by 3%. The guidance for the second quarter meets expectations, with total revenue expected to remain flat and non-GAAP operating profit margin between 33% and 34%. Despite changes in the market environment, the long-term outlook remains unclear, but management is slightly optimistic about the advertising outlook and maintains its full-year revenue guidance
Read more
2025-05-21 (businessupturn.com)
Zydus share price: Nomura sees 29% upside, upbeat on US growth and vaccine contribution |
Nomura has retained its buy rating on Zydus Lifesciences with a target price of ₹1,140, implying an upside of nearly 29% from the current market price of ₹884.45. The brokerage acknowledges a Q4 EBITDA miss but remains optimistic about FY26, citing better-than-expected guidance. The Q4 EBITDA came in below expectations, primarily due to lower contribution […]
Read more
2025-05-19 (businessupturn.com)
Nomura upgrades CreditAccess to neutral, sets target at Rs 1,090, sees 9% downside from current CMP |
Nomura has upgraded CreditAccess Grameen to neutral and raised the target price to Rs 1,090, implying a downside of around 9% from the current market price of Rs 1,200.00.The brokerage noted that the company posted a net profit of Rs 472 million in Q
Read more
2025-05-16 (aastocks.com)
Nomura: TENCENT (00700.HK) 1Q Results Still Impressive; TP Elevated to $670 AASTOCKS Financial News - Latest News
Despite macro uncertainties, TENCENT (00700.HK) still delivered impressive 1Q25 results, Nomura published a research report saying. The online game an...
Read more
2025-05-16 (businessupturn.com)
Nomura maintains 'Buy' on eClerx with Rs 3,600 target; Q4 revenue, margins beat estimates |
Nomura has reiterated its 'Buy' rating on eClerx Services, assigning a target price of Rs 3,600 per share, indicating a potential upside from the current market price of Rs 3,152. The brokerage cited a strong Q4 performance and a healthy deal pipelin
Read more
2025-05-14 (businessupturn.com)
Nomura retains 'Reduce' on Siemens after weak Q2 results; strong order inflows fail to offset margin decline |
Nomura has retained its 'Reduce' rating on Siemens Ltd with a target price of ₹2,630, following the company's weak operational performance for Q2 of its September-ended financial year (Q2SY25). While revenue and order inflows held strong, significant
Read more
Used by 100+ compliance teams and analysts